GlassScriptPhysician profile
Janice M Dworkin
NPI 1528289147
$1,907.45
in general payments reported to CMS, 2019-2025
13 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $25.97 · 2021: $163 · 2022: $177 · 2023: $371 · 2024: $420 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.40 |
| Education | $254.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $790.46 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Arcutis Biotherapeutics, INC. | $417.64 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $174.66 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $149.56 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.97 | 2019 | |
| Celgene Corporation | $125.00 | 2019 | |
| Journey Medical Corporation | $39.46 | 2019 | |
| Glenmark Therapeutics INC. | $25.00 | 2019 | |
| Krystal Biotech INC | $15.67 | 2025 | Vyjuvek |
| Encore Dermatology INC. | $14.27 | 2020 | |
| Ucb, INC. | $14.23 | 2022 | |
| Incyte Corporation | $12.96 | 2022 | |
| Organon LLC | $2.57 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Dworkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.